DK1263730T3 - Aminderivater til behandling af apoptose - Google Patents
Aminderivater til behandling af apoptoseInfo
- Publication number
- DK1263730T3 DK1263730T3 DK01927666T DK01927666T DK1263730T3 DK 1263730 T3 DK1263730 T3 DK 1263730T3 DK 01927666 T DK01927666 T DK 01927666T DK 01927666 T DK01927666 T DK 01927666T DK 1263730 T3 DK1263730 T3 DK 1263730T3
- Authority
- DK
- Denmark
- Prior art keywords
- amine derivatives
- substituted amine
- apoptosis
- treatment
- well
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title abstract 4
- 230000006907 apoptotic process Effects 0.000 title 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00810128A EP1125925A1 (de) | 2000-02-15 | 2000-02-15 | Amin-Derivate zur Behandlung von Apoptosis |
PCT/EP2001/001579 WO2001060798A1 (en) | 2000-02-15 | 2001-02-13 | Amine derivatives for the treatment of apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1263730T3 true DK1263730T3 (da) | 2008-03-10 |
Family
ID=8174551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01927666T DK1263730T3 (da) | 2000-02-15 | 2001-02-13 | Aminderivater til behandling af apoptose |
Country Status (12)
Country | Link |
---|---|
US (1) | US6770656B2 (de) |
EP (2) | EP1125925A1 (de) |
JP (1) | JP4875272B2 (de) |
AT (1) | ATE383339T1 (de) |
AU (1) | AU784086C (de) |
CA (1) | CA2397651A1 (de) |
DE (1) | DE60132309T2 (de) |
DK (1) | DK1263730T3 (de) |
ES (1) | ES2296747T3 (de) |
IL (2) | IL151172A0 (de) |
PT (1) | PT1263730E (de) |
WO (1) | WO2001060798A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074667A2 (en) * | 2002-03-01 | 2003-09-12 | Blood Center Research Foundation | Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
AU2003249713A1 (en) * | 2002-07-03 | 2004-01-23 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
AU2003302084A1 (en) * | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
US20080096824A1 (en) * | 2003-02-28 | 2008-04-24 | Shigemi Matsuyama | Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
CA2716664C (en) | 2008-03-07 | 2016-10-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds |
US8604074B2 (en) | 2009-01-09 | 2013-12-10 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
US8575170B2 (en) | 2010-02-26 | 2013-11-05 | The Regents Of The Unversity Of Colorado, A Body Corporate | Flurbiprofen analogs and methods of use in treating cancer |
CN103415289B (zh) | 2010-07-07 | 2017-04-12 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
EP2899183B1 (de) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituierte Tetrahydroisochinolinverbindungen als Faktor-XIA-Hemmer |
WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
AR088456A1 (es) | 2011-10-14 | 2014-06-11 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia |
US9701676B2 (en) | 2012-08-24 | 2017-07-11 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP2906552B1 (de) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidinsubstituierte tetrahydroisochinoline als factor xia inhibitoren |
EP2906541B1 (de) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidin- und aminsubstituierte tetrahydroisochinoline als factor xia inhibitoren |
SI2906551T1 (en) | 2012-10-12 | 2018-05-31 | Bristol-Myers Squibb Company | CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR |
CN105228996B (zh) | 2013-03-25 | 2017-11-28 | 百时美施贵宝公司 | 作为因子XIa抑制剂的含取代唑类的四氢异喹啉 |
WO2015070234A2 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
TWI790421B (zh) | 2014-01-31 | 2023-01-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物 |
NO2760821T3 (de) | 2014-01-31 | 2018-03-10 | ||
EP3189047B1 (de) | 2014-09-04 | 2018-12-26 | Bristol-Myers Squibb Company | Diamidmakrocyclen als fxia-inhibitoren |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
JOP20200059A1 (ar) | 2017-09-13 | 2020-03-12 | Amgen Inc | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها |
US20220389028A1 (en) * | 2019-05-31 | 2022-12-08 | Case Western Reserve University | Bax inhibitors and uses thereof |
WO2021211742A1 (en) * | 2020-04-14 | 2021-10-21 | The General Hospital Corporation | Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW9580A1 (en) * | 1979-05-21 | 1981-12-23 | Ici Ltd | 1-phenyl-2-aminoethanol derivatives |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
KR100244372B1 (ko) * | 1991-05-09 | 2000-03-02 | 조슈아 에스.보저 | 신규한 면역 억제성 화합물 |
FR2711990B1 (fr) * | 1993-11-05 | 1995-12-08 | Exsymol Sa | Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires. |
AU3352495A (en) | 1994-08-30 | 1996-03-22 | Barbara Ann Spruce | Agents for inducing apoptosis and applications of said agents in therapy |
ATE465149T1 (de) * | 1996-02-28 | 2010-05-15 | Ariad Pharma Inc | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
JP4473355B2 (ja) * | 1997-11-19 | 2010-06-02 | 武田薬品工業株式会社 | アポトーシス抑制剤 |
AR019322A1 (es) * | 1998-06-18 | 2002-02-13 | Smithkline Beecham Corp | Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento |
EP1094063A1 (de) * | 1999-10-18 | 2001-04-25 | Applied Research Systems ARS Holding N.V. | 9-(Piperazinylalkyl)carbazole als Bax-Modulatoren |
-
2000
- 2000-02-15 EP EP00810128A patent/EP1125925A1/de not_active Withdrawn
-
2001
- 2001-02-13 WO PCT/EP2001/001579 patent/WO2001060798A1/en active IP Right Grant
- 2001-02-13 IL IL15117201A patent/IL151172A0/xx active IP Right Grant
- 2001-02-13 AU AU54640/01A patent/AU784086C/en not_active Ceased
- 2001-02-13 PT PT01927666T patent/PT1263730E/pt unknown
- 2001-02-13 EP EP01927666A patent/EP1263730B1/de not_active Expired - Lifetime
- 2001-02-13 AT AT01927666T patent/ATE383339T1/de not_active IP Right Cessation
- 2001-02-13 ES ES01927666T patent/ES2296747T3/es not_active Expired - Lifetime
- 2001-02-13 DE DE60132309T patent/DE60132309T2/de not_active Expired - Lifetime
- 2001-02-13 DK DK01927666T patent/DK1263730T3/da active
- 2001-02-13 CA CA002397651A patent/CA2397651A1/en not_active Abandoned
- 2001-02-13 US US10/182,745 patent/US6770656B2/en not_active Expired - Fee Related
- 2001-02-13 JP JP2001560184A patent/JP4875272B2/ja not_active Expired - Fee Related
-
2002
- 2002-08-11 IL IL151172A patent/IL151172A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1125925A1 (de) | 2001-08-22 |
US6770656B2 (en) | 2004-08-03 |
PT1263730E (pt) | 2008-02-11 |
DE60132309D1 (de) | 2008-02-21 |
AU5464001A (en) | 2001-08-27 |
EP1263730B1 (de) | 2008-01-09 |
ATE383339T1 (de) | 2008-01-15 |
DE60132309T2 (de) | 2009-01-02 |
EP1263730A1 (de) | 2002-12-11 |
WO2001060798A1 (en) | 2001-08-23 |
AU784086B2 (en) | 2006-02-02 |
ES2296747T3 (es) | 2008-05-01 |
JP2003523332A (ja) | 2003-08-05 |
IL151172A (en) | 2008-04-13 |
IL151172A0 (en) | 2003-04-10 |
JP4875272B2 (ja) | 2012-02-15 |
AU784086C (en) | 2006-09-14 |
CA2397651A1 (en) | 2001-08-23 |
US20030216427A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1263730T3 (da) | Aminderivater til behandling af apoptose | |
IL149163A0 (en) | Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
PT1263724E (pt) | Novos compostos | |
IS6658A (is) | Ný efnasambönd | |
AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
DK1265862T3 (da) | 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
IS2293B (is) | Arýl sambrædd asapólýsýklísk efnasambönd | |
EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
NO20020282L (no) | Nytt difenyl-piperidinderivat | |
PT992509E (pt) | Novos derivados macrolidos | |
DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
SE0101038D0 (sv) | Novel compounds | |
DK1216245T3 (da) | Farmaceutisk aktive sulfonylhydrazidderivater | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
ATE253359T1 (de) | Antithrombotische mittel | |
ATE384714T1 (de) | Pyrazolderivate | |
BRPI0409957A (pt) | imidazolin-2-ilaminofenil amidas | |
PA8450901A1 (es) | Derivados de eritromicina | |
DE60110233D1 (de) | Neue n-(2-phenyl-3-aminopropyl)naphtamide |